Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too

2026-01-13 15:09:52 ET

The last time I spoke about Inhibrx Biosciences, Inc. ( INBX ) it was in a Seeking Alpha article entitled " Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing ." With respect to this article, I mentioned that the company had achieved positive results from its phase 2 registrational ChonDRAgon study, which evaluated the use of ozekibart [INBRX-109] in unresectable or metastatic conventional chondrosarcoma patients. Based on this, the company was planning to file a Biologics License Application [BLA] for ozekibart to treat these specific patients in Q2 of 2026....

Read the full article on Seeking Alpha

For further details see: